INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Back to India Desk
2026/10/06Banking, Fintech & InsuranceEnterprise Tech, Cloud & AI
🇮🇳 India Edition • Banking, Fintech & InsuranceRDU GLOBAL CORRESPONDENT
VERIFIED WIRE INTELLIGENCE

"Divi’s Labs, TVS Motor Seen as Likely Replacements in Nifty March 2027 Review"

Divi’s Laboratories and TVS Motor Company are emerging as leading candidates to enter the Nifty index in the March 2027 review, potentially displacing Max Healthcare Institute and HDFC Life, according to Quiddity Leaderboard. The anticipated reshuffle could trigger estimated passive inflows of about $824 million, although the review remains at an early stage and the final composition may still change.

Divi’s Labs, TVS Motor Seen as Likely Replacements in Nifty March 2027 Review

R

RDU Global Wire

BFSI & Fintech Desk

New Delhi, India 06 Oct 2026, 08:07 AM IST•4 min read

Divi’s Laboratories and TVS Motor Company are emerging as leading candidates to enter the Nifty index in the March 2027 review, potentially displacing Max Healthcare Institute and HDFC Life, according to Quiddity Leaderboard. The anticipated reshuffle could trigger estimated passive inflows of about $824 million, although the review remains at an early stage and the final composition may still change.

Market participants are already positioning for a possible reshuffle in India's benchmark equity indices, with Divi's Laboratories and TVS Motor Company emerging as the strongest contenders to replace Max Healthcare Institute and HDFC Life in the Nifty at the March 2027 review. The assessment, cited by Quiddity Leaderboard, points to a likely wave of passive buying if the changes materialise, with estimated inflows of roughly $824 million tied to index-tracking funds.

Index Watch Begins

The March 2027 review is still in its early phase, and the eventual outcome is far from settled. Even so, the current ranking dynamics suggest that the two prospective entrants have built enough market capitalisation and liquidity momentum to challenge existing constituents. In India's index ecosystem, such changes matter well beyond symbolism: inclusion in the Nifty can lift trading volumes, broaden institutional ownership and improve a company's visibility among global and domestic investors.

For Divi's Laboratories, a potential entry would reinforce the market's preference for large, liquid and export-oriented pharmaceutical names with strong earnings visibility. For TVS Motor, inclusion would underscore the continuing re-rating of India's two-wheeler and mobility manufacturing space, especially as investors reward companies with scale, brand strength and resilient operating performance. Both names have benefited from sustained investor interest, making them credible candidates in a benchmark that is increasingly shaped by free-float market value and liquidity metrics.

Passive Flows In Focus

The estimated $824 million in inflows reflects the mechanical impact of index inclusion, as funds and exchange-traded products that track the Nifty would need to buy the incoming constituents and reduce exposure to the outgoing names. Such flows can be powerful in the short term, often supporting share prices ahead of and immediately after implementation. However, analysts typically caution that the effect is temporary unless backed by durable fundamentals.

Max Healthcare Institute and HDFC Life, if they are ultimately removed, would not be leaving because of any deterioration in business quality alone. Rather, index reviews are governed by relative ranking, and companies can fall out when other constituents outrun them in size or trading depth. That makes the March 2027 exercise a reminder that benchmark membership is dynamic, not permanent, even for well-regarded names in healthcare and financial services.

The broader implication is that India's equity market continues to deepen, with sector leadership shifting as investors rotate toward companies that combine scale, earnings momentum and high liquidity. The likely movement also highlights how benchmark composition can influence capital allocation across the market, especially in an environment where passive investing has become a more significant force.

Early-Stage Rebalancing

Quiddity Leaderboard's view should be read as a projection rather than a final call. Index committees typically assess a range of factors before any review is confirmed, and the picture can change materially over time. Further alterations to the Nifty 100 rankings are also expected, indicating that the broader universe of large-cap names may see additional movement before the March 2027 review is completed.

For investors, the key question is not only who enters or exits, but what the changes say about the underlying market hierarchy. If Divi's Laboratories and TVS Motor do secure inclusion, it would signal continued strength in pharmaceuticals and automotive manufacturing, while also reflecting the market's ongoing tilt toward companies with consistent liquidity and institutional appeal.

Until the review is finalised, the likely reshuffle remains a developing market story rather than a done deal. But even at this stage, the contours are clear: benchmark changes could redirect substantial capital, reshape sector representation and reinforce the importance of index eligibility as a driver of stock performance in India's large-cap universe.

Editorial & Verification Notice

Reported by RDU Global Correspondent. Formatted and verified using real-time institutional and journalistic wire feeds. Independent reporting adhering to the RDU Global Editorial Code of Conduct.

Entity Intelligence & Connected Dossiers

Cross-referenced topic files, verified public records, and institutional tracking

Knowledge Graph
📍Locations & Geopolitics:

Related Coverage